Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics

Area of Science:

• Oncology
• Clinical Trial Design
• Molecular Therapeutics

Background:

• Traditional Phase II trials often rely on tumor histology, which may not accurately reflect the molecular drivers of cancer.
• Novel anti-cancer agents are increasingly developed with specific molecular targets, necessitating adaptive trial designs.
• Evaluating targeted therapies requires methods that can identify patient populations most likely to respond based on molecular profiles.

Purpose of the Study:

• To describe and evaluate a novel Phase II study design for assessing targeted anti-cancer agents.
• To shift the focus from tumor histology to molecular pathogenesis in early-phase cancer drug development.
• To introduce a histology-independent, target-specific trial methodology.

Main Methods:

• An enrichment design enrolling patients across histologies with a specific molecular target (Target X).
• Incorporation of a randomized discontinuation of a drug (Drug Y) after an initial treatment phase.
• Evaluation of cystostatic activity by comparing continued drug treatment versus placebo in patients with stable disease.

Main Results:

• Currently evaluating lapatinib in HER-2 amplified solid tumors using this design.
• Patients receive 12 weeks of lapatinib; responders continue, progressive disease is removed, and stable disease is randomized.
• Primary endpoints include objective response rate and 12-week progression-free survival post-randomization.

Conclusions:

• The target-specific, histology-independent, randomized discontinuation design is effective for developing targeted therapeutics.
• This design offers an attractive alternative to traditional Phase II approaches for precision oncology.
• It facilitates the efficient evaluation of novel targeted agents by focusing on molecular drivers of cancer.